用于炎症治疗的磷脂酰丝氨酸修饰胞外囊泡纳米递药系统的初步构建与评价

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (4042 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract ］Objective： Preliminarily to construct and evaluate phosphatidylserine (PS)-modified macrophage-derived extracellular vesicles (EVs) nanocarriers (PS-EVs@Que) for delivering quercetin (Que) and study the role of PS-EVs@Que in the treatment of inflammation. Methods： EVs were isolated from macrophages by ultracentrifugation, Que was loaded into EVs by ultrasonication (EVs@Que), and finally PSEVs@Que was prepared by incubating PS into EVs@Que solution, the morphology, particle size, drug loading capacity and encapsulation efficiency of formulations were also evaluated; cellular uptake of EVs and PS-modified EVs were determined by immunofluorescence. Macrophages were treated with LPS, LPS+EVs@Que, LPS+PSEVs@Que and control group respectively, and the expression of iNOS, a marker on the surface of macrophages, were detected by Western Blotting; the expression of inflammatory factors TNF-α and IL-6 were detected by Enzyme-Linked Immunosorbent Assay (ELISA). Results： The prepared PS-EVs@Que presented a circular-like vesicle structure with an average particle size of (118.45±0.97) nm, drug loading capacity of (8.59±0.16)% and encapsulation efficiency of (20.08±0.52)%. The uptake results showed that the modification of PS resulted in better phagocytosis of EVs by macrophages and enhanced the uptake of EVs by macrophages. Macrophage iNOS protein expression reduced in the PS-EVs@Que group compared with other groups (P<0.01), and the expression of inflammatory factors TNF-α and IL-6 were significantly inhibited (P<0.01). Conclusion： In this study, we successfully constructed and evaluated a nanomedicine delivery system, which improved the bioavailability of Que, inhibited the polarization of pro-inflammatory phenotype (M1 type) of macrophages, and reduced the pro-inflammatory factors, providing a reference for novel nanomedicines treatment of inflammatory diseases.

Key words：

Received: 18 May 2023

Fund:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Jie
	CHANG Tian
	ZHANG Jing
	GE Guangrong
	CHEN Jiuyuan
	HUO Qiang
	CHENG Xiu

Cite this article:

YAN Jie,CHANG Tian,ZHANG Jing等. Preliminary construction and evaluation of a phosphatidylserine-modified extracellular vesicles nano-drug delivery system for inflammation therapy

[J]. Journal of Jiangsu University(Medicine Edition), 2024, 24(01): 79-83.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2024/V24/I01/79

［1］Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases［J］. Int J Mol Sci, 2018, 19(6): 1801.

［2］Svedberg FR, Brown SL, Krauss MZ, et al. The lung environment controls alveolar macrophage metabolism and responsiveness in type 2 inflammation［J］. Nat Immunol, 2019, 20(5): 571-580.

［3］司丽君, 王雪, 王林林, 等. 槲皮素的抗炎免疫及部分机制研究［J］. 中国医药导报, 2021, 18(27): 26-29, 34.

［4］Hu Y, Gui Z, Zhou Y, et al. Quercetin alleviates rat osteoarthritis by inhibiting inflammation and apoptosis of chondrocytes, modulating synovial macrophages polarization to M2 macrophages［J］. Free Radic Biol Med, 2019, 145: 146-160.

［5］Jiang W, Zhang H, Wu J, et al. CuS@ MOFbased welldesigned quercetin delivery system for chemophotothermal therapy［J］. ACS Appl Mater Interfaces, 2018, 10(40): 34513-34523.

［6］Huang J, Wang Q, Chu L, et al. Liposomechitosan hydrogel bead delivery system for the encapsulation of linseed oil and quercetin: Preparation and in vitro characterization studies［J］. Lwt, 2020, 117: 108615.

［7］Xu Z, Hu L, Ming J, et al. Selfgated porous organic polymer as drug delivery system for pH stimuliresponsive controlled quercetin release［J］. Micropor Mesopor Mat, 2020, 303: 110259.

［8］Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a nextgeneration drug delivery platform［J］. Nat Nanotechnol, 2021, 16(7): 748-759.

［9］Xia Q, Zhang Y, Li Z, et al. Red blood cell membranecamouflaged nanoparticles: a novel drug delivery system for antitumor application［J］. Acta Pharm Sin B, 2019, 9(4): 675-689.

［10］Yunna C, Mengru H, Lei W, et al. Macrophage M1/M2 polarization［J］. Eur J Pharmacol, 2020, 877: 173090.

［11］Koh YC, Yang G, Lai CS, et al. Chemopreventive effects of phytochemicals and medicines on M1/M2 polarized macrophage role in inflammationrelated diseases［J］. Int J Mol Sci, 2018, 19(8): 2208.

［12］Poerio N, Caccamo NR, La Manna MP, et al. Phosphatidylserine liposomes reduce inflammatory response, mycobacterial viability, and HIV replication in coinfected human macrophages［J］. J Infect Dis, 2022, 225(9): 1675-1679.

［13］Lotter C, Alter CL, Bolten JS, et al. Incorporation of phosphatidylserine improves efficiency of lipid based gene delivery systems［J］. Eur J Pharm Biopharm, 2022, 172: 134-143.

［14］Tandon P, Abrams ND, Carrick DM, et al. Metabolic regulation of inflammation and its resolution: current status, clinical needs, challenges, and opportunities［J］. J Immunol, 2021, 207(11): 2625-2630.

［15］Cutolo M, Campitiello R, Gotelli E, et al. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis［J］. Front Immunol, 2022, 13: 867260.

［16］张煜敏, 张桢烨, 钱玲玲, 等. 槲皮素通过AKT/FOXO3信号通路保护糖尿病大鼠心肌细胞［J］. 江苏大学学报(医学版), 2021, 31(3): 185-189.

［17］陈雯, 连方, 辛欣, 等. 外泌体在多囊卵巢综合征中的研究进展［J］. 江苏大学学报(医学版), 2023, 33(3): 213-218.

［18］Lemke G. How macrophages deal with death［J］. Nat Rev Immunol, 2019, 19(9): 539-549.